The Center for Hematologic Malignancies (CHM) serves patients with blood cancers, including leukemia, lymphoma, and myeloma. Our leadership in the field allows us to support emerging research and move discoveries from the lab to the patient’s bedside.

The past decade has seen remarkable advances in the biology and treatment of blood cancers. Molecular-based therapies for specific disease subtypes have led to new treatment approaches and continued innovation in stem cell transplantation, both of which have had a major impact on patients at Memorial Sloan Kettering and worldwide.

Our world-renowned laboratory scientists and clinical investigators strive daily to make further paradigm-changing discoveries that improve outcomes for patients with blood cancers. CHM is designed to accelerate scientific discovery, to support investigations into new research directions, and to serve as a node for translational research between laboratory and clinical investigators with a shared interest in hematologic malignancies.